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Germline mutations of BRCA1 confer hereditary
susceptibility to breast and ovarian cancer. However,
somatic mutation of BRCA1 is infrequent in spo-
radic breast cancers. The BRCA1 protein C terminus
(BRCT) domains interact with multiple proteins and
are required for BRCA1’s tumor-suppressor function.
In this study,wedemonstrated thatAbraxas, aBRCA1
BRCT domain-interacting protein, plays a role in tu-
mor suppression. Abraxas exerts its function through
binding toBRCA1 to regulateDNArepair andmaintain
genome stability. Both homozygous and heterozy-
gous Abraxas knockout mice exhibited decreased
survival and increased tumor incidence. The gene en-
coding Abraxas suffers from gene copy loss and so-
matic mutations in multiple human cancers including
breast, ovarian, and endometrial cancers, suggesting
that mutation and loss of function of Abraxas may
contribute to tumor development in human patients.INTRODUCTION
The hereditary breast and ovarian cancer tumor suppressor
protein BRCA1 plays critical roles in DNA repair, cell-cycle
checkpoint control, and maintenance of genomic stability. The
BRCA1 C terminus (BRCT) domains constitute a phosphopep-
tide recognition domain that binds specifically to phosphopepti-
des containing a pSPxF (phosphor-serine-proline-x-phenylala-
nine) motif (Manke et al., 2003; Rodriguez et al., 2003; Yu et al.,
2003). BRCT domains are frequently targeted by many clinically
important mutations, and most of these mutations disrupt the
binding surface of the BRCT domains to phosphorylated pep-
tides (Bouwman et al., 2013; Glover, 2006). Mice carrying a
BRCT mutant of BRCA1 defective in recognition of phosphory-
lated proteins are prone to tumor development, indicating that
BRCT phosphoprotein recognition is required for BRCA1 tumorsuppression (Shakya et al., 2011). Three proteins, Abraxas (also
known as Abra1, FAM175A, and CCDC98), Bach1 (also known
as Brip1 and FancJ), and CtIP (also known as RBBP8), directly
interact with the BRCA1 BRCT domains through the pSPxFmotif
in a phosphorylation-dependent manner forming mutually exclu-
sive complexes, which were thus named as the A, B, and C com-
plexes of BRCA1 (Greenberg et al., 2006; Kim et al., 2007; Liu
et al., 2007; Wang et al., 2007; Yu et al., 2003).
The BRCA1 A complex, composed of Abraxas and other com-
ponents including NBA1, BRE, BRCC36, and Rap80, is found to
play an important role in mediating the recruitment of BRCA1 to
DNA double-strand breaks (DSBs) for DNA damage checkpoint
regulation and efficient DNA repair. In the BRCA1 A complex,
Abraxas appears to be a central adaptor protein, because it har-
bors several domains necessary for the interactions with BRCA1
and other components in the complex (Wang, 2012). Abraxas in-
teracts with the BRCT domains of BRCA1 through the pSPxF
motif at its C terminus. The N terminus of Abraxas including
a MPN domain is important for interactions with NBA1, BRE,
and Rap80. In addition, Abraxas dimerizes with BRCC36
through a coiled-coil domain present on both proteins. As a vital
component of the BRCA1-A complex, Abraxas appears to be a
key player in the DNA damage response. However, its role
in DNA repair, BRCA1 signaling, and tumor suppression is not
clear.
In this study, by generating an Abraxas-deficient mousemodel
and further analysis, we demonstrated that Abraxas is a tumor
suppressor gene and the interaction of Abraxas and BRCA1 is
critical for Abraxas’ function in repair of DNA and maintenance
of genome stability. We also showed evidence that loss of
Abraxas function by copy number loss, reduced expression,
and mutations occurs in multiple human cancers.
RESULTS
Abraxas-Deficient Mice Are Viable and Display
Increased Sensitivity to Ionizing Radiation
To explore the function of Abraxas in vivo, we generated
knockout mice of the Abraxas/Fam175A gene encodingCell Reports 8, 807–817, August 7, 2014 ª2014 The Authors 807
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Figure 1. Abraxas Plays Critical Roles in
Cellular Responses to DNA Damage In Vivo
(A) Generation of Abraxas-deficient mice. A dia-
gram of mouse Abraxas alleles generated for
deletion of exon 5. NEO, neomycin resistance
gene.
(B) Abraxas protein is absent in Abraxas/MEFs.
Cell lysates from Abraxas+/+ and Abraxas/MEFs
were separated in SDS-PAGE gel. Western blots
were carried out with antibodies tomouse Abraxas
and tubulin.
(C) Abraxas-deficient mice show increased
sensitivity to ionizing radiation. Five-week-old
wild-type and Abraxas/ littermates were sub-
jected to 7.5 Gy IR. Mice were monitored daily and
survival was assessed by Kaplan-Meir curve and
log-rank test.
(D) Abraxas/MEF cells are sensitive to IR, MMC,
and PARP1 inhibitor (Olaparib) as measured by
clonogenic survival assay. Cells were incubated
with indicated doses of MMC or PARP1 inhibitor
during the course of incubation. For colony sur-
vival studies, cells were seeded at low density and
treated with respective doses of DNA-damaging
agents. Colonies were counted and normalized to
untreated samples to calculate percent survival.
Error bars represent SD across triplicates. Three
independent experiments were performed.the Abraxas protein (Figures 1 and S1). We first generated a
gene-targeting construct containing exon 5 of the Abraxas
genomic sequence flanked by two loxP sites and a selection
marker NEO gene flanked by two FRT sites inserted in the
intron region between exons 4 and 5 of the Abraxas gene (Fig-
ure 1A). Upon deletion of exon 5, due to a frameshift in the
targeted allele, a premature STOP codon will be encountered
immediately after exon 4. Any processed exon-5-deleted tran-
script would generate a truncated product of 97 amino acids
that lacks all functional domains and should be inactive (Fig-
ure S1). The construct was introduced into murine embryonic
stem cells ESCs for homologous recombination, replacing
one copy of the Abraxas gene. Properly targeted ESCs were
identified by Southern blot and used for the generation of
chimeric mice (Figure S1). The chimeras were then crossed
with C56BL/6 mice to identify germline transmission and gener-
ation of AbraxasNeo/+ mice. Abraxas+/D animals were generated
after Cre recombinase-mediated deletion of exon 5. Intercross-
ing of Abraxas+/D mice indicated that AbraxasD/D mice were808 Cell Reports 8, 807–817, August 7, 2014 ª2014 The Authorsviable and born at expected Mendelian
ratios. RT-PCR using primers located
in exons 5 and 6 revealed disruption
of the full-length Abraxas transcript in
AbraxasD/D mouse embryonic fibroblasts
(MEFs) (Figure S1). Sequencing of the
RT-PCR products spanning exons 2
to 6 confirmed that the exon-5-deleted
transcript contains a premature STOP
codon and has likely undergone
nonsense-mediated decay indicated bydecreased transcript levels (Figure S1). The loss of Abraxas
full-length protein was also confirmed in AbraxasD/D MEFs by
immunoblotting (Figures 1B and S1) with an antibody recog-
nizing the C-terminal region of the mouse Abraxas protein.
Abraxas/ (AbraxasD/D) mice did not exhibit any gross devel-
opmental defects and were indistinguishable from their WT
littermates after birth. Thus, unlike BRCA1 and the BRCA1-
BRCT-interacting CtIP, Abraxas is not required for embryonic
and postnatal development.
To determine whether Abraxas plays a role in the DNA damage
response in vivo, we treated WT and Abraxas/ mice with
7.5 Gy ionizing radiation (IR). After treatment, the majority of
Abraxas/ mice died between 7 and 28 days postirradiation,
whereas none of the WT mice died during this same time frame
(Figure 1C). Thus, Abraxas-null mice are more sensitive to IR.
Similarly, MEF cells prepared from Abraxas/ mice displayed
increased sensitivity to IR, the DNA crosslinking agentmitomycin
C (MMC), and poly ADP ribose polymerase (PARP) inhibitor Ola-
parib (Figure 1D). Abraxas forms IR-induced DNA damage foci
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Figure 2. Abraxas-BRCA1 Interaction Is Crucial for Double-Strand Break Repair in Response to IR
(A) Abraxas/ cells were defective in repairing damaged DNA after 2 Gy IR treatment. Wild-type and Abraxas/MEF cells were treated with 2 Gy IR, incubated
for indicated times, fixed, and stained with gH2AX antibodies followed by appropriated secondary antibodies. At least 300 cells were counted for each time point
for quantification. Cells containing more than ten foci were counted as positive. Error bars represent SD across triplicates.
(B) Abraxas/ cells were defective in DNA repair using comet assay. DNA damage was assessed by comet assay in either untreated or 5-Gy-treated primary
MEF cells at indicated time points. Tail moments were quantified from 50 cells, and the mean value is calculated. The experiment has been repeated three times.
(C) Loss of Abraxas resulted in decreased sister chromatid exchange (SCE). After labeling with BrdU for 20 hr, cells were treated with 250 nMmitomycin C (MMC)
and analyzed for SCE 12 hr post MMC treatment. Data are representative of 30 metaphases per sample.
(D) Generation of Abraxas mutants.
(E)WT but notmutants of Abraxas rescued the increased sensitivity of Abraxas/MEF cells to IR asmeasured by clonogenic survival assay. Error bars represent
SD across triplicates. Three independent experiments were performed.
(F) Mutants of Abraxas failed to rescue DNA repair deficiency of Abraxas/MEF cells. DNA damage was assessed by comet assay in either untreated or 5-Gy-
treated cells 6 hr post IR. Tail moments were quantified from 50 cells, and damage percentages were calculated based on 150 cells per sample.(IRIF) (Kim et al., 2007; Liu et al., 2007; Wang et al., 2007). The
IRIF formation of Abraxas was undetectable in Abraxas/
MEF cells as a result of loss of the Abraxas protein (Figure S1).
Consistent with the previous notion that Abraxas plays a critical
role in the accumulation of BRCA1 to DNA damage sites and for-
mation of the BRCA1-A complex, the IRIF formation of BRCA1
and Rap80 in Abraxas/MEF cells were diminished (Figure S1)
(Wang and Elledge, 2007; Wang et al., 2009). Together, these
data indicate Abraxas plays an important role in the DNA dam-
age response in vivo in mice.
Abraxas-BRCA1 Interaction Is Crucial for DSB Repair in
Response to IR
Abraxas knockout mice and MEF cells are sensitive to IR, indi-
cating a deficiency in DNA repair. In order to investigate whether
Abraxas-BRCA1 interaction is needed for repair of DSBs, we
first examined whether Abraxas/ MEF cells are defective in
DNA repair. Using staining of gH2AX as a marker for damagedDNA, we found that the WT cells continued to show a decline
in the percentage of cells containing gH2AX foci over time
and by 7 hr posttreatment returned to pre-IR levels, whereas
the Abraxas/ cells consistently displayed a high percentage
of cells with gH2AX foci through the duration of the experi-
ment, indicating a deficiency in DNA repair (Figure 2A). This is
confirmed in a comet assay to measure DNA breaks and
monitor cells’ ability to repair induced DNA breaks. Compared
to WT cells, Abraxas/ cells appeared to have much higher
percentage of cells having unrepaired DNA (increased tail
moments) at 6 hr post IR treatment (Figures 2B and S2). As a
comparison, BRCA1-deficient Brca1D11/D11 MEF cells were
also defective in DNA repair in the comet assay (Figure S2).
With previous implications of Abraxas in homologous recombi-
nation (Coleman and Greenberg, 2011; Hu et al., 2011; Wang
et al., 2007), we investigated the role of Abraxas in homologous
recombination by analysis of sister chromatid exchange.
Compared to WT cells, Abraxas/ cells showed reduced sisterCell Reports 8, 807–817, August 7, 2014 ª2014 The Authors 809
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Figure 3. Abraxas Is Not Required for Pro-
tecting HU-Stalled Replication Fork
(A) Schematic of experimental design.
(B) BRCA1 deficiency results in shortening of
stalled replication fork. Fiber assay was performed
with UWB1+BRCA1 (BRCA1+/+) or UWB1
(BRCA1/) isogenic cell lines following 4 mM
hydroxyurea (HU) treatment. UWB1 is a BRCA1-
null ovarian cancer cell line. Themean fiber lengths
were calculated and indicated (BRCA1/,
p < 0.0001).
(C) Abraxas deficiency does not result in short-
ening of stalled replication fork. Fiber assay was
performed with two pairs of Abraxas+/+ or
Abraxas/ MEFs. The mean fiber lengths are
calculated and indicated (Abraxas/, p = 0.073).
The experiments were repeated three times with
two pairs of Abraxas MEF cell lines (also see Fig-
ure S7) and with reversing the analogs and the HU
pulse with the same result. More than 50 fibers
were measured for each condition.chromatid exchanges per metaphase (Figure 2C), indicating
that Abraxas is required for homologous recombination.
Consistent with this, accumulation of Rad51 (Rad51 foci),
a central participant in homologous recombination, to the
DNA damage sites was also decreased in Abraxas/ cells
(Figure S2).
We then examined whether interaction with BRCA1 is
needed for Abraxas’ function in DNA repair. We generated a
S404A mutant of mouse Abraxas protein with the serine resi-
due (S404) present in the pSPxF motif mutated to alanine. Mu-
tation of a corresponding serine mutant S406A of the human
Abraxas protein abolished the binding of Abraxas to BRCA1
(Wang et al., 2007). Because the formation of the BRCA1-A
complex is important for recruitment of BRCA1 to DNA damage
sites, we also generated mutants of Abraxas that fail to form an
intact BRCA1-A complex, a coiled-coil deletion (DCC) mutant,
and a W99E mutant (Figure 2D). Previously, it was shown dele-
tion of the coiled-coil domain in human Abraxas (DCC) disrupts
the binding of Abraxas to BRCC36 (Wang et al., 2009) and
mutation of W99E in the MPN domain of Abraxas disrupts inter-
action with other members of the BRCA1-A complex including
Rap80, BRE, NBA1, and BRCC36 (Patterson-Fortin et al.,
2010). These mutants, when expressed, behaved as expected
for interactions with BRCA1 and other A-complex proteins in
immunoprecipitation analysis (Figure S2). In the analysis of
Abraxas/ MEFs infected with retroviral constructs stably ex-
pressing HA-tagged mouse Abraxas wild-type or mutants, the
Abraxas mutants failed to increase the survival of Abraxas/
MEFs in response to IR (Figure 2E). The mutants also failed
to rescue the DNA repair deficiency of Abraxas/ cells using
a comet assay to assess DNA repair efficiency (Figure 2F).810 Cell Reports 8, 807–817, August 7, 2014 ª2014 The AuthorsTogether, these results indicate that the
interaction of Abraxas with BRCA1, as
well as the formation of the BRCA1-A
complex, is critical for efficient DNA
repair. It suggests that Abraxas is partof the BRCA1 signaling in cellular resistance to DNA-damaging
agents and DNA repair.
Abraxas Is Not Required for Protecting Stalled
Replication Forks
BRCA1 is implicated in a repair-independent mechanism in pro-
tecting stalled replication forks from degradation to maintain
genome stability (Schlacher et al., 2012). We tested whether
Abraxas is required for such a role. As previously shown,
BRCA1-deficient cells show significant shortening of fork length
following hydroxyurea (HU) treatment, indicating degradation
of stalled replication forks. However, unlike BRCA1, loss of
Abraxas resulted in subtle changes in the length of stalled repli-
cation forks (Figures 3 and S3). In addition, Abraxas did not
appear to be required for efficient replication restart after HU
treatment (data not shown), consistent with published observa-
tion that BRCA1 is not required for replication recovery
(Schlacher et al., 2012). It suggests that the role of BRCA1 in pro-
tecting stalled replication fork is independent of Abraxas.
Abraxas Interacts with FancD2 and Is Recruited to
Crosslinked DNA Damage Sites for Repair
Because Abraxas/ cells are sensitive to the DNA crosslinking
agentMMC (Figure1D),weexaminedwhetherAbraxas is involved
in DNA crosslink repair. Abraxas accumulated to DNA damage
sites in cells treatedwithMMC (Figure 4A). In addition, Abraxas in-
teracted with FancD2 in coimmunoprocipitation assays, and the
interaction appeared not to be induced byDNA-damaging agents
such as IR orMMC treatment (Figure 4B). Rap80, another compo-
nent in the BRCA1-A complex, also interacted with FancD2,
and, similarly, the interaction was independent of DNA damage
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Figure 4. Abraxas Is Involved in Crosslinked
DNA Damage Repair
(A) Abraxas accumulated to DNA damage sites in
response to crosslinking agent MMC. Abraxas+/+
and Abraxas/ MEFs were treated with 1.5 mM
MMC and collected at 6 hr posttreatment for
immunofluorescence analysis.
(B) Abraxas interacts with FancD2. Coimmuno-
precipitation of Abraxas and FancD2 were carried
out using lysates of 293T human cells untreated or
treated with 10 Gy IR or 1.5 mM MMC and anti-
bodies against FancD2 or Abraxas. Asterisk rep-
resents a band of IgG heavy chain.
(C) Abraxas and Rap80 accumulated to cross-
linked DNA damage sites. The eChIP analysis of
Abraxas and Rap80 enrichment to a defined
psoralen lesion in the absence (293 XL) or pres-
ence (EBNA XL) of DNA replication in 293 cells.
Error bars for chromatin fraction and eChIP ana-
lyses represent SDs derived from three inde-
pendent experiments. Recruitment of ERCC1, a
critical component of the nucleotide excision
repair (NER) lesion bypass-based DNA interstrand
crosslink repair, was used as a control.
(D) MEF cells were treated with MMC with indi-
cated doses for 1 hr followed by two washes of
PBS and addition of fresh medium for incubation
at 37C for 2 weeks. Rescue of the increased
sensitivity to MMC of the Abraxas/MEF cells as
measured by clonogenic survival assay. Error bars
represent SD across triplicates. Experiments were
repeated three times. Another set of data is pre-
sented in Figure S8.(FigureS4).We then testedwhetherAbraxas isdirectly recruited to
DNA crosslink sites. Using an episomal replication-based chro-
matin IP (eCHIP) assay, which allows the identification of DNA
damage response proteins at crosslinked DNA lesions in the
context of Epstein-Barr nuclear antigen-1 (EBNA)-dependent
episomal replication (Shen et al., 2009), we found that Abraxas
and Rap80 were significantly enriched on the crosslink-bearing
substrate compared with the unmodified substrate (Figure 4C).
In addition, the enrichment was further enhanced by DNA replica-
tion of the crosslinked substrate, as indicated by the dramatic in-
creaseof its enrichment incells expressingEBNA. It thussuggests
that the further recruitment of Abraxas andRap80 depends on the
presence of stalled replication forks. Because BRCA1 interacts
with FancD2 and mediates FancD2 foci formation after treatment
with MMC (Bunting et al., 2012; Garcia-Higuera et al., 2001; Van-
denberg et al., 2003), we wished to examine whether AbraxasCell Reports 8, 807–81affects FancD2 recruitment or ubiquitina-
tion in response to crosslink agent. Due
to lack of antibodies recognizing mouse
FancD2 protein, we tested whether
Abraxas is required for FancD2 foci forma-
tion or FancD2 ubiquitination after MMC
treatment in humancells treatedwith small
hairpin RNAs against Abraxas. We found
that Abraxas is not required for FancD2
foci formation or ubiquitination in responseto MMC treatment (Figure S4). Thus, Abraxas does not appear to
play a role in BRCA1-mediated recruitment of FancD2 suggesting
Abraxas might have an additional role independent of BRCA1 in
the crosslink repair. If this is true, Abraxas mutant not interacting
with BRCA1 might be able to rescue the defects of Abraxas/
cells in crosslink repair.We thus testedwhether the S404Amutant
could rescue the sensitivity of Abraxas/ cells to MMC. We
noticed that indeed, the S404A mutant appeared to, at least
partially, rescue the MMC sensitivity of Abraxas/ cells (Figures
4D and S4), suggesting that Abraxas possesses a role indepen-
dent of BRCA1 in the crosslink repair.
Abraxas-BRCA1 Interaction Is Crucial for Maintaining
Genome Stability
Tomonitor the effects of Abraxas deficiency on genome stability,
we prepared metaphase chromosome spreads from MEF cell7, August 7, 2014 ª2014 The Authors 811
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Figure 5. Abraxas-BRCA1 Interaction Is
Critical for Maintaining Genomic Stability
(A and B) Abraxas/ cells displayed increased
spontaneous DNA breaks. Primary Abraxas+/+
MEF cells were used in the metaphase spread
analysis for spontaneous DNA breaks. Represen-
tative image and the percentage of cells containing
at least one DNA break are shown. Quantified data
are based on >300 metaphases per sample from
three replicate analyses.
(C and D) Abraxas/ cells displayed increased
severity of chromosomal aberrations, consisting of
multiple DNA breaks, fusions, and radial struc-
tures, in response to IR. Metaphase spread anal-
ysis was carried out with primary early passage
Abraxas+/+ and Abraxas/MEF cells treated with
2 Gy IR. Percentage of normal and abnormal
metaphase was quantitated. Normal metaphase
contains no breaks. Abnormal metaphase con-
tains a single break, more than two breaks, a
fusion, a radial structure, or a combination of
breaks and fusion/radial structures (complex). The
percentage of each type of abnormal metaphase
was also calculated. Quantified data are based
on >40 metaphases per sample. Error bars
represent SD.
(E) Mutants of Abraxas failed to rescue genome
instability of the Abraxas/MEF cells. Metaphase
spread analysis was carried out in immortalized
Abraxas/ MEFs complemented with empty
vector, wild-type or mutants of Abraxas 4 hr after
treated with 2 Gy IR. Metaphases consisting
‘‘single break,’’ ‘‘multiple breaks (>1),’’ or ‘‘other’’
(chromosomal aberrations of fusion/radial, or a
combination of breaks and fusion/radial structure)
were quantified. Quantified data are based on >40
metaphases per sample.lines. Untreated Abraxas/ MEFs showed a nearly 3-fold in-
crease of spontaneous single chromatid breaks compared to
wild-type cell lines (Figures 5A and 5B), suggesting an intrinsic
defect in genome stability in Abraxas/ cells. When treated
with 2Gy IR,Abraxas/ cells displayed amore severe deficiency
in maintaining genome stability. IR-treated Abraxas/MEFs ex-
hibited a significant increase in the percentage of cells containing
chromosomal abnormalities compared to WT cells. In addition,
whereas chromosomal aberrations in WT cells are mostly single
breaks and very rarely fusions and radial structures, IR-treated
Abraxas/ MEFs manifested multiple breaks per metaphase
as well as significant increases in chromosomal fusion events
and radial structures (Figures 5C and 5D). Thus, loss of Abraxas
results in the accumulation of both spontaneous and IR-induced
chromosomal defects. In addition, DAPI staining of Abraxas/
MEFs displayed an increased incidence of abnormal nuclear
morphology in Abraxas/ cells compared to WT. Nuclear frag-
mentation and micronuclei were more frequently observed in812 Cell Reports 8, 807–817, August 7, 2014 ª2014 The AuthorsAbraxas-deficient cells, which also sug-
gest elevated levels of chromosomal
breaks and defects (Figure S5).
We then tested whether the interaction
of Abraxas and BRCA1 is important forAbraxas tomaintain genome stability (Figure 5E). The IR-induced
chromosome aberrations in Abraxas-null cell were greatly
reducedwhen the null cells were complemented with expression
of WT Abraxas but not with the S404A mutant that is defective in
interacting with BRCA1. In addition, mutants that disrupt the
formation of the BRCA1-A complex also failed to reduce the
chromosome aberrations asmuch as theWT Abraxas. Together,
these results indicate that the interaction of Abraxas with
BRCA1, as well as the formation of the BRCA1-A complex, is
critical for Abraxas’ function in maintaining genome stability.
Abraxas Suppresses Tumor Development in Mice
Because Abraxas interacts with BRCA1 and is critical for main-
taining genome stability, we examined whether Abraxas plays
a tumor suppressor role in mice. We monitored survival and
tumor development in a cohort of Abraxas+/+, Abraxas+/, and
Abraxas/ mice during organismal aging. Compared to WT
mice, Abraxas+/ and Abraxas/ mice had a significantly
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Figure 6. Abraxas+/ and Abraxas/ Mice
Exhibit an Increased Susceptibility to Tumor
Formation
(A) Disease-free survival analyzed by the Kaplan-
Meier method (p < 0.0001). Amatched cohort of 33
Abra1+/+, 45 Abra1+/, and 31 Abra1/mice were
monitored over 30 months for spontaneous tumor
development.
(B) Spontaneous tumor incidence in Abraxas+/+,
Abraxas+/, and Abraxas/ mice. From the mice
we analyzed, one out of six Abraxas+/+mice (17%),
14 out of 21 Abraxas+/mice (67%), and seven out
of 11 Abraxas/ mice (64%) developed tumor.
(C) Summary of the spontaneous tumor spec-
trum. Pathologic analysis revealed that one
Abraxas+/+mouse developed tumor that is most
likely histocytic sarcoma; among 14 Abraxas+/
mice that developed tumor, two mice developed
both lymphoma and liver tumor, one mouse
developed lung adenocarcinoma, liver tumor, and
lymphoma, and one mouse developed histocytic
sarcoma; seven Abraxas/ mice developed
lymphoma.
(D) Lymphoma in spleen, lymph node, and
lymphoid infiltrates to nonlymphoid organs.
Representative histological images (H&E staining)
of detected tumors are shown.reduced life span exhibiting decreased disease-free survival
(Figure 6A). Pathologic analysis of the tissue slides from the
end-stage mice revealed a clear increase in the tumor incidence
in Abraxas+/ and Abraxas/mice. From the mice we analyzed,
over 60% of Abraxas/ nullizygous and Abraxas+/ heterozy-
gous mice developed cancer including lymphoma and other
types of tumors (Figure 6B). Although tumors were detected
in some Abraxas+/ or Abraxas/ mice as early as 8 months
of age, the mean age of Abraxas/ and Abraxas+/ mice that
developed tumor was 17 and 24 months, respectively. Tumors
developed in Abraxas+/ and Abraxas/ mice were primarily
lymphoma and a few cases of solid tumors in lung and liver (Fig-
ure 6C). Lymphoma prominently involved the spleen and lymph
nodes including the mesenteric and cervical lymph nodes (Fig-
ure S6). The majority of the lymphomas developed in Abraxas+/
and Abraxas/ mice were found to infiltrate various nonlym-
phoid organs, including liver, lung, kidney, and intestine (Fig-
ure 6D). The majority of the lymphomas appeared to be B cell
lymphoma indicated by B cell marker B220-positive staining in
immunohistochemistry (IHC) and B220 and immunoglobulin (Ig)
M double-positive staining in flow cytometry analysis of tumor
cells (Figure S6). To investigate whether tumor formation in
Abraxas+/ mice is attributed to haploid insufficiency, we per-
formed microdissection to isolate tumor cells and analyzed the
Abraxas genotype by PCR and Abraxas expression by western
blot. The tumor samples analyzed appeared to retain the wild-
type allele and expression of Abraxas indicating the remaining
wild-type allele is expressed (Figure S7), suggesting that hap-
loinsufficiency of Abraxas leads to tumorigenesis in mice.
Together, these data indicate that Abraxas is a tumor suppressor
in mice.Indication of Loss of Abraxas/FAM175A Function in
Human Tumors
Because knockout ofAbraxas leads to spontaneous tumordevel-
opment in mice, we investigated whether Abraxas is also critical
for tumor suppression in human. To this end, we analyzed the
Abraxas expression level, gene copy number alteration, and
somatic mutation status in various human tumors in the TCGA
(http://cancergenome.noih.gov/) and COSMIC (Forbes et al.,
2010) database. Reduced Abraxas gene expression is observed
in multiple types of cancers (bladder, breast, cervical, head and
neck, renal papillary, endometrial, and thyroid) compared to
those from autologous normal tissues (Figure 7A). Gene copy
number loss of the Abraxas locus at chromosome 4q21 is
frequently found in ovarian, breast (especially basal subtype),
lung, and colon cancers, which involves the loss of whole chro-
mosome 4q arm (Figure 7B; Table S1). In addition, copy loss of
Abraxas correlated well with reduced Abraxas expression in
ovarian and breast cancer (Figure 7C), suggesting loss of gene
copy number is one of the major mechanisms to downregulate
Abraxas expression in these tumors. Furthermore, somaticmuta-
tions of Abraxas are found in endometrial, colon, lung, liver, kid-
ney cancers, and in leukemia (Tables S1 and S2) with the highest
mutation rate found in endometrial cancer (2.5%). Despite the
low mutation frequency, the distribution of mutation sites in the
Abraxas gene displays a remarkable pattern indicative of tar-
geted inactivation by human tumors. Among all 26 nonsynony-
mous mutations found in Abraxas, five nonsense mutations and
one frameshift insertion were found to generate truncated or
abnormal protein products that lack the pSPxF motif and inca-
pable of binding to the BRCA1 protein. Structural and biochem-
ical analysis of BRCA1 BRCT domains bound to optimizedCell Reports 8, 807–817, August 7, 2014 ª2014 The Authors 813
Figure 7. Compromise of Abraxas Function in Human Cancers
by Reduced Gene Expression, Copy Number Loss, and Somatic
Mutation
(A) Downregulation of AbraxasmRNA expression in multiple tumors. Box plots
of logged RNaseq RSEM were made for multiple cancers. BLCA, bladder;
BRCA, breast; CESC, cervical; HNSC, head and neck; KIRC, renal clear cell;
KIRP, renal papillary; LIHC, liver; LUAD, lung adenocarcinoma; LUSC, lung
squamous carcinoma; PRAD, prostate; THCA, thyroid; UCEC, endometrial
cancer.
(B) Copy number loss of Abraxas/FAM175A locus (4q21) in ovarian cancer and
basal breast cancer, but not in luminal A breast cancer. Cumulative gene copy
number alterations were drawn from SNP6 data to show frequency of gene
copy number changes on each chromosome. Pink/green, copy number gains/
losses; the red line marks the position of Abraxas gene on chromosome 4
(chr4).
(C) Correlation of reduced Abraxas expression level with copy number loss in
breast and ovarian cancer.
(D) A graphical summary of nonsilent somatic mutations of Abraxas gene
identified in human tumors. Each triangle represents a mutation identified from
an individual tumor.
814 Cell Reports 8, 807–817, August 7, 2014 ª2014 The Authorsphosphopeptides has revealed that the phenylalanine residue in
the pSPxFmotif is essential for the recognition of thismotif by the
BRCT domains (Rodriguez et al., 2003; Shiozaki et al., 2004; Wil-
liams et al., 2004). The finding of an amino acid mutation of
phenylalanine (F409C) in the pSPxF motif located at the very C
terminus of Abraxas in one endometrial tumor also highlights
the importance of Abraxas binding to BRCA1. Notably, the
same R252* nonsense mutation within the coiled-coil domain
was found twice in two endometrial tumor samples. Another
seven mutations were found inside the MPN domain, which is a
domain critical for the formation of the BRCA1-A complex. In
addition, seven missense mutations were gathered around a
small region including a bipartite nuclear localization signal
(NLS) (Table S2). A germline mutation of Abraxas (R361Q) in
familiar breast cancer patients in this region was previously re-
ported to disrupt nuclear localization of Abraxas (Solyom et al.,
2012). Taken together, our cancer genomics data analyses
strongly argue that Abraxas is a bona fide tumor suppressor
gene in human and Abraxas-BRCA1 interaction is likely to be
important for the role of Abraxas in tumor suppression.
DISCUSSION
Abraxas interacts with BRCA1 and is required for accumulation
of BRCA1 to DNA damage sites playing important roles in the
DNA damage response (Kim et al., 2007; Liu et al., 2007; Wang
et al., 2007). In vivo study of this gene is necessary to further
understand its role in DNA repair and tumor suppression. In addi-
tion, assessing the clinical relevance of this gene in human can-
cer patients will provide invaluable insights to the function of
this gene in tumor suppression. In this study, we demonstrate
Abraxas is essential for DNA repair and tumor suppression in vivo
in mouse. In addition, reduced expression, gene copy loss, and
mutation of Abraxas are also observed in multiple types of
human tumor including breast and ovarian cancer.
Analysis from a number of mouse models for BRCA1 inactiva-
tion has indicated that BRCA1 is essential for embryonic devel-
opment and conditional inactivation of BRCA1 in mammary
and ovarian tissues predisposes to tumor (Dine and Deng,
2013). Abraxas-null mice are viable and born at expected Men-
delian ratios, indicating that Abraxas gene, unlike BRCA1, is
not essential for embryonic development and thus is not likely
to play a major role in BRCA1’s function in embryonic develop-
ment. Importantly, Abraxas is essential for tumor suppression.
Both Abraxas-null and heterozygous mice are tumor prone
with over 60% tumor incidence developing lymphomas and
other tumors. The tumor-suppressing function of Abraxas is
likely due to its role in DNA repair. Ability to efficiently repair
damaged DNA is crucial for cells to maintain chromosomal sta-
bility and prevention of cancer. Our study showed that Abraxas
not only is involved in the IR-induced double-strand break repair,
but also plays a role in the crosslink repair. As a result, compared
to WT cells, Abraxas/ cells displayed increased spontaneous
breaks and IR-induced chromosome aberrations including mul-
tiple breaks, fusions, and radial structures. In addition, lack
of Abraxas in mice results in hypersensitivity of mice to IR and
MEF cells to DNA-damaging agents such as IR, MMC, and
PARPi. Repair of DNA crosslinking lesions require Fanconi
anemia (FA) proteins. A FA core complex consisting of FANCA-
C, E-G, L, andM is formed for damage-inducedmonoubiquitina-
tion of FancD2/FancI (Kee and D’Andrea, 2010). Both Abraxas
and its interacting protein Rap80 interact with FancD2 and are
recruited to DNA crosslink damage sites, and the recruitment
appears to depend on the presence of stalled replication forks,
suggesting that Abraxas is involved in replication-mediated
crosslink repair. Because Abraxas does not appear to be
required for FancD2 ubiquitination and recruitment to crosslink
damage sites, it is more likely the function of Abraxas and the
BRCA1-A complex in DNA crosslink repair is downstream
or independent of FancD2 ubiquitination. A group of breast
cancer susceptibility (BRCA) genes including BRCA2/FancD1,
BACH1/FancJ, PALB2/FancN (Wang, 2007) have been shown
to be enriched on crosslink DNA damage sites and involved in
homologous recombination but not required for monoubiquitina-
tion of the FancD2/FancI complex (Shen et al., 2009). The exact
mechanism of how Abraxas is involved in DNA repair is still not
clear. Nevertheless, despite undefined mechanism, Abraxas is
required for efficient DNA repair and plays a critical role in main-
taining genome stability and tumor suppression.
Although it has been shown that the BRCT domains of BRCA1
are essential for BRCA1’s tumor-suppressor function (Shakya
et al., 2011), it remains largely unknown how the BRCT-associ-
ated complexes transmit the BRCA1 signaling in mechanisms
of the DNA damage response and whether the BRCA1 interac-
tion is important for tumor suppression. Our study evaluated
the importance of Abraxas-BRCA1 interaction in DNA repair
and genomic stability. Mutant of Abraxas lacking the BRCA1
interaction motif (S404A mutant) fails to rescue the deficiency
ofAbraxas/ cells in DNAdamageDSB repair and chromosome
stability. Although it is not yet clear the role of Abraxas-BRCA1
interaction in tumor suppression in mice, given its importance
in DNA repair and maintenance of genomic stability, the
Abraxas-BRCA1 interaction is likely to play a critical role in tumor
suppression as well. The importance of Abraxas and BRCA1
interaction in tumor suppression is also suggested by identifica-
tion of loss of function mutation in Abraxas resulting in truncated
products lacking BRCA1-binding motif and a F409C mutation in
the pSPxF BRCA1 BRCT binding motif predicted to abolish the
binding to BRCA1 (Shiozaki et al., 2004; Williams et al., 2004)
in human cancer patients. Thus, Abraxas is part of the BRCA1
signaling in DNA repair, maintenance of genome stability and
likely tumor suppression as well. However, it is also not surpris-
ing that Abraxas does not participate in all the function of
BRCA1. For example, Abraxas, unlike BRCA1, is not required
for embryonic development or stalled replication fork protection.
On the other hand, Abraxas might have additional roles than
BRCA1 signaling in DNA repair and tumor suppression, such
as a BRCA1-independent role in the crosslink repair.
Abraxas appears to be a tumor suppressor gene in human
fromanalysis of the human cancer genomics. Among the 26 non-
synonymous mutations identified in tumors in the Abraxas gene,
at least six (23%) are inactivating mutants, which result in trun-
cated product of the protein that lose the binding to BRCA1.
According to the ‘‘20/20’’ rule proposed by Vogelstein et al.
(2013) for predicting driver oncogene/tumor suppressor genes,
Abraxas could be classified as a tumor suppressor gene withmore than 20% of the mutations are inactivating. Abraxas also
fits the criteria as a tumor suppressor gene using the Tumor Sup-
pressor and Oncogene (TUSON) Explorer, a recently proposed
computational method for predicting oncogene/tumor suppres-
sor genes (Davoli et al., 2013). The fact that many missense mu-
tations of Abraxas occur at functional domains of Abraxas critical
for binding to BRCA1 or interactions with other components of
the BRCA1-A complex suggests the functional importance of
these domains in prevention of cancer. This is consistent with
our experimental findings that the MPN, coiled-coil, and pSPxF
motif are important for Abraxas’ role in DNA repair and genomic
stability. We also identified a mutational ‘‘hot spot’’ in Abraxas
that includes a previously identified bipartite nuclear localization
signal (NLS). A germline Abraxas mutation (R361Q) from familiar
breast cancer patients was reported to disrupt nuclear localiza-
tion of Abraxas in this region (Solyom et al., 2012). It is important
to note that further analysis is needed to determine whether
these mutations are truly pathogenic.
Hereditary germline mutations or genetic/epigenetic inactiva-
tion of BRCA1 predispose women to breast and ovarian cancer.
Although tumors developed in Abraxas/ mice are mostly lym-
phoma, it is known that genetic background plays a role in both
the type of tumor that develops and tumor latency inmice (Done-
hower and Lozano, 2009). Indeed, bioinformatics analysis of the
TCGA database indicates that loss/reduced function of Abraxas
may contribute to multiple types of human cancers including
breast and ovarian cancer. The chromosome locus of Abraxas/
FAM175A (4q21) is frequently lost in ovarian and breast tumors.
Interestingly, in breast cancer, loss of 4q21 is most frequently
found in basal but less common in luminal tumors. Although it is
possible multiple tumor suppressor gene including Abraxas exist
at 4q21 are lost during chromosome 4 (Chr4) copy loss in tumors,
lossof copycorrelateswellwith reducedexpressionofAbraxas in
these tumors, suggesting loss of gene copy number is one of the
major mechanisms to downregulate Abraxas expression in these
tumors and reduced Abraxas expression may play a role in the
development of ovarian and breast tumor. In breast cancer and
ovarian cancer, somatic BRCA1 mutation rate is low. Thus, loss
of ABRA1 expression may be a surrogate of BRCA1 functional
loss. This is consistent with Abraxas plays an important role in
BRCA1 signaling, mediating at least partly of BRCA1’s role in
double-strand break repair and maintaining genome stability.
Taken together, our study implicates Abraxas is a bona fide
tumor suppressor playing a role in DNA repair and maintaining
genome stability. It is also likely to be part of the BRCA1 signaling
that contributes to tumor suppression.EXPERIMENTAL PROCEDURES
Generation of Abraxas-Null Mice
Details are described in the Supplemental Experimental Procedures. All exper-
iments with mice followed protocols approved by the MD Anderson Cancer
Center Institutional Animal Care and Use Committee, protocol 110812132,
and conformed to the guidelines of the United States Animal Welfare Act
and the National Institutes of Health.
Mouse Radiosensitivity Assay
Five-week-old WT and Abraxas/ littermates were subjected to 7.5 Gy IR.
Mice were monitored daily for survival, and Kaplan-Meier survival curesCell Reports 8, 807–817, August 7, 2014 ª2014 The Authors 815
were generated. A log-rank test was used for statistical analysis. Thirteen
Abraxas+/+ mice and 11 Abraxas/ mice were included in the study.
Plasmids and Antibodies
Retroviral expression constructs for expression of wild-type and Abraxas
mutants were made using MSCV vectors containing HA-Flag tag at the
N terminus as described (Schlabach et al., 2008). Deletion mutants of
Abraxas were generated by cloning the corresponding cDNA fragments
into the aforementioned retroviral vector. Site-directed mutagenesis was
performed with the QuickChange II site-directed mutagenesis kit (Strata-
gene) to generate Abraxas point mutations. Purified Gst-tagged C-terminal
fragment of Abraxas (281–407 aa) was used for Abraxas antibody produc-
tion. Other antibodies used were BRCA1 (M20, Santa Cruz Biotechnology),
gH2AX (Upstate), HA (Cell Signaling Technology), FancD2 (Santa Cruz,
GeneTex).
Cell Culture and Generation of MEFs
MEFs were generated from 13.5-day embryos using standard procedures.
Immortalization was carried out by standard 3T3 assay. About 3 3 105 cells
were seeded every 3 days. 293T cells and MEFs were cultured in DMEM sup-
plementedwith 10% fetal bovine serum and 100 mg/ml penicillin/streptomycin.
Stable cells were generated by infecting 293T cells or MEFs with retrovirus
containing HA-tagged proteins, followed by puromycin selection.
Immunofluorescence
Cells grown on coverslips were fixed in 3% paraformaldehyde/2% sucrose
fixative solution for 10 min, permeablized with 0.5% Triton X-100, blocked
with 5% bovine serum albumin, and incubated with primary antibodies at
37C for 1 hr. Appropriate secondary antibodies conjugated to Alexa 488,
555, 647 (Invitrogen), and Cy3 (Amersham Biosciences) fluorophores
were used. All images were captured on a Nikon 2000U inverted microscope
using a Photometric CoolSnap HQ camera.
Clonogenic Survival Assay
MEF cells were seeded at low density and treated with various DNA-damaging
agents, i.e., ionizing radiation, MMC, etc. Cells were then cultured at 37C for
10–14 days to allow colonies to form. Colonies were stained with 2% crystal
violet/50% methanol. Colonies containing 50 or more cells were counted,
and statistical data were analyzed by t test analysis.
Analysis of Metaphase Chromosomes
Cells were seeded to obtain 50%–70% confluency following overnight culture.
For IR-induced chromosome breaks, cells were irradiated with 2Gy IR and
cultured for 2 hr. Cells were then incubated in 25 ng/ml colcemid (Invitrogen)
for 1–3 hr. Cells were harvested by mitotic shake off, washed, incubated in
hypotonic solution (0.06 M KCl), and fixed in 10 ml of Carnoy’s fixative. Meta-
phase spreads were prepared on glass slides and dried. Dried slide prepara-
tions were stained with Giemsa or DAPI and examined for the presence of
chromatid breaks, fusions, and structural defects.
Comet Assay
Trypsinized 2 3 105 cells were pelleted and suspended in 1 ml ice-cold 1 3
PBS buffer followed by standard protocol. Details are described in the Supple-
mental Experimental Procedures. Nuclear DNA on slides was visualized
under a fluorescent microscope (Leica DM4000 B), and images were captured
at 4003 magnifications using Leica DFC 300 FX color camera. To measure
levels of DNA damage, 50 cells of each sample were analyzed for tail moment
(a.u.) by the CometScore software (TriTek). Quantitative results of tail moment
were graphed by Prism 5 software.
DNA Fiber Assays
Cells were labeled with CldU (100 mM) for 30 min, washed, labeled with IdU
(250 mM) for 30 min, and then treated with HU (4 mM) for 4 hr. Alternatively,
cells were labeled with CldU, followed by HU, and then IdU for the same times
indicated. DNA fibers were spread as described (Jackson and Pombo, 1998).
Briefly, cells were diluted 1:10 with unlabeled cells, and 2.5 ml of the cells
suspended in PBS (106 cell/ml) were spotted on to a glass slide. After briefly816 Cell Reports 8, 807–817, August 7, 2014 ª2014 The Authorsdrying, 7.5 ml of spreading buffer (0.5% SDS, 200mMTris-HCl [pH 7.4], 50mM
EDTA) was dropped on the cells and incubated for 10 min. Slides were tilted
(15) to spread lysed cells across the slide. Slides were air-dried, fixed in
methanol:acetic acid (3:1) for 3 min, and stored at 4C overnight before
staining. CldU and IdU tracts were detected using Mouse anti-BrdU (BD
Biosciences) (1:50) and Rat-anti-BrdU (OBT0030, AbDSerotec) (1:100) 1 hr
at 37C, followed by Alexa 488 anti-mouse (1:100) and Cy3-Anti Rat (Jackson
ImmunoResearch) (1:100) 30 min at 37C, and mounted with VectaShield
(Vector Laboratories). Fibers were imaged at 403 with a Zeiss Axio Observer
inverted microscope and Metamorph software for acquisition. Statistics were
performed using a two-tailed Mann-Whitney test with Prism 6 (GraphPad)
software.
eChIP Assay
Preparation of lesion-defined substrates and the eChIP assay were carried out
according to protocols described earlier (Shen et al., 2009)
Histology
Tissues were fixed in 10% buffered formalin (Fisher Scientific). Paraffin blocks
were cut at 5 mm and were stained with hematoxylin and eosin (H&E) stain. For
immunohistochemistry, B220 (550286; BD Pharmingen), Ki67 (VP-RM04; Vec-
tor Labs), CD3 (ab5690; Abcam) antibodies were used. Images were obtained
using a Nikon Eclipse90i microscope.
Cancer Genomics Data analysis
Level 3 RNaseqV2 data for gene expression and level 3 SNP array data for
gene copy numbers were downloaded from The Cancer Genome Atlas
(TCGA) data portal (https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.
htm). Somatic mutation data including mutation rate and gene copy loss rate
were downloaded from the COSMIC website (http://cancer.sanger.ac.uk/
cancergenome/projects/cosmic/).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.06.050.
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